课题基金 / 基金详情

Using p53 Knock-In Mice to Understand p53's Role in Pancreatic Cancer

Using p53 Knock-In Mice to Understand p53's Role in Pancreatic Cancer
使用 p53 敲入小鼠了解 p53 在胰腺癌中的作用
批准号:
7707938
负责人:
LAURA D ATTARDI
金额:
$18.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2011-06-30

项目摘要

项目成果

LAURA D ATTARDI的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):胰腺癌是癌症相关死亡的第四大原因,而且几乎总是一种致命的疾病。这种癌症从侵袭前状态发展到转移的侵袭状态与P53肿瘤抑制基因的突变有关。虽然P53通过诱导细胞周期停滞、衰老或凋亡来抑制癌症,但其在体内的分子作用机制尚不清楚。P53不仅具有转录激活活性,而且还具有多种其他生化活性,如调节转录抑制、DNA复制和重组、线粒体膜完整性和中心体复制。为了开始确定对抑制胰腺癌进展重要的P53分子活性,我们建议通过产生和分析一组表达不同P53突变的P53敲入小鼠株来解决P53转录激活和抑制功能对肿瘤抑制的重要性。利用转基因小鼠,在天然p53启动子的控制下表达突变,在其中正常细胞可以在体外和在生物体的生理环境中进行研究,应该可以为p53在肿瘤抑制中的作用机制提供明确的见解。我们以前产生了表达p53突变体p5325,26的敲入小鼠,该突变体对大多数但不是所有的p53靶基因的反式激活造成严重损害,并保留了抑制肺癌发展的能力。这些观察结果表明,p5325,26抑癌基因的功能是由残留的p53反式激活或另一种P53活性所解释的。我们将首先利用KRAS激活的胰腺癌小鼠模型检测该突变体抑制胰腺癌进展的能力,从而确定胰腺肿瘤抑制是否需要完整的P53反式激活潜能。如果p5325,26显示活性,将通过检测表达完全缺陷的反式激活突变p5325,26,53,54的小鼠来区分有限反式激活与另一种p53功能对肿瘤抑制的重要性。此外,将通过产生表达p53转录抑制缺陷变体的小鼠来评估转录抑制对p53功能在阻止胰腺癌进展中的重要性。我们建议进一步开发一个细胞培养模型系统,用于更详细地研究P53介导的胰腺肿瘤抑制的机制。总之,这些研究将确定基因是否必须被P53激活和/或抑制,或者其他P53活性是否对其抑制胰腺癌发展的能力至关重要,并将对这种致命疾病的未来更好的癌症治疗方法的开发具有巨大的实用价值。 公共卫生相关性:胰腺癌是美国癌症死亡的第四大原因,几乎总是致命的。因此,了解这种疾病的基础是非常重要的,以便能够更有效地治疗和治愈它。这项研究旨在阐明一种名为p53的基因是如何防止胰腺癌发展的,最终目标是设计出更好的癌症预防和治疗策略。
英文摘要
DESCRIPTION (provided by applicant): Pancreatic cancer is the 4th leading cause of cancer-associated deaths, and it is virtually always a fatal disease. The progression of this cancer from a preinvasive state to a metastatic, invasive state is associated with mutation of the p53 tumor suppressor gene. While p53 suppresses cancer by inducing cell cycle arrest, senescence or apoptosis in response to stress signals, its molecular mechanism of action in vivo remains unclear. p53 displays activity as a transcriptional activator, but it also has a variety of other biochemical activities, in regulating transcriptional repression, DNA replication and recombination, mitochondrial membrane integrity, and centrosome duplication. To begin to define the p53 molecular activities important for suppressing pancreatic cancer progression, we propose to address the importance of p53 transcriptional activation and repression functions for tumor suppression through the generation and analysis of a panel of p53 knock-in mouse strains expressing different p53 mutants. The use of knock-in mice, in which mutants are expressed under the control of the native p53 promoter, and in which normal cells can be studied both ex vivo and in the physiological context of the organism, should provide definitive insight into the mechanism of p53 action in tumor suppression. We previously generated knock-in mice expressing a p53 mutant, p5325,26, that is severely impaired for the transactivation of most, but not all, p53 target genes and that retains the ability to suppress lung cancer development. These observations suggest that p5325,26 tumor suppressor function is accounted for by either residual p53 transactivation or another p53 activity. We will first examine the ability of this mutant to inhibit pancreatic cancer progression using a well-characterized mouse model of pancreatic cancer driven by activated KRas expression, and we will thus determine if full p53 transactivation potential is required for tumor suppression in the pancreas. If p5325,26 displays activity, the importance of limited transactivation versus another p53 function for tumor suppression will be distinguished by examining knock-in mice expressing a mutant totally defective for transactivation, p5325,26,53,54. In addition, the importance of transcriptional repression for p53 function in blocking pancreatic cancer progression will be assessed by generating mice expressing a repression-defective variant of p53. We propose further to develop a cellular culture model system for more detailed mechanistic studies of p53-mediated tumor suppression in the pancreas. Together, these studies will determine whether genes must be activated and/or repressed by p53, or whether other p53 activities are essential for its ability to suppress pancreatic cancer development, and will have great utility for the future development of better cancer therapies for this deadly disease. PUBLIC HEALTH RELEVANCE: Pancreatic cancer is the 4th leading cause of cancer deaths in the US and is nearly always fatal. It is therefore very important to understand the basis of this disease in order to be able to more effectively treat and cure it. This research aims to elucidate how a gene known as p53 acts to prevent the development of pancreatic cancer, with the ultimate goal of devising better prevention and treatment strategies for cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pancreatic Cancer Development: Genetic and Immune Regulation
  • 批准号:
    10704071
  • 项目类别:
  • 资助金额:
    $198.25万
  • 财政年份:
    2021
  • 负责人:
    LAURA D ATTARDI
  • 依托单位:
Project 1: Elucidating the genetics and cell of origin of pancreatic cancer initiation
  • 批准号:
    10187125
  • 项目类别:
  • 资助金额:
    $43.8万
  • 财政年份:
    2021
  • 负责人:
    LAURA D ATTARDI
  • 依托单位:
Project 1: Elucidating the genetics and cell of origin of pancreatic cancer initiation
  • 批准号:
    10704080
  • 项目类别:
  • 资助金额:
    $40.95万
  • 财政年份:
    2021
  • 负责人:
    LAURA D ATTARDI
  • 依托单位:
Pancreatic Cancer Development: Genetic and Immune Regulation
  • 批准号:
    10187124
  • 项目类别:
  • 资助金额:
    $212.95万
  • 财政年份:
    2021
  • 负责人:
    LAURA D ATTARDI
  • 依托单位:
海外基金